ProCE Banner Activity

Expanding Role of MRAs in Heart Failure: Bridging the Gap Between Evidence and Clinical Practice

Clinical Thought

There remains a gap in translating research into clinical practice across the heart failure (HF) spectrum regarding mineralocorticoid receptor agonists as an add-on therapy. Learn what current evidence suggests and why healthcare professionals must stay up-to-date on new and emerging therapies for HF.

Released: April 22, 2025

Expiration: April 21, 2026

Share

Provided by

Provided by Clinical Care Options

ProCE Banner

Supporters

This activity is supported by an independent medical education grant from Bayer HealthCare Pharmaceuticals, Inc.

Bayer HealthCare Pharmaceuticals Inc.

Disclosure

Primary Author

Scott D. Solomon, MD: researcher: Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Boston Scientific, Cytokinetics, Edgewise, Eidos/BridgeBio, Gossamer, GlaxoSmithKline, Ionis, Lilly, NIH/NHLBI, Novartis, Novo Nordisk, Respicardia, Sanofi, Pasteur, Tenaya, Theracos, US2.AI; consultant/advisor/speaker: Abbott, Action, Akos, Alexion, Alnylam, American Regent, Amgen, Ancardio, Arena, AstraZeneca, Bayer, Bristol Myers Squibb, Cardior, Cardurion, CellProThera, Corvia, Cytokinetics, Dinaqor, GlaxoSmithKline, Intellia, Lexico, Lilly, Moderna, Novartis, Roche, Theracos, Tremeau, Quantum Genomics, Tenaya, Sanofi-Pasteur, Sarepta, Valo.